Navigation Links
Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis

ere adjudicated by a blinded, independent central adjudication committee. The study was not powered to show a dose response with PRT054021 or efficacy of PRT054021 versus enoxaparin.

About PRT054021 -- Portola's Factor Xa Inhibitor

PRT054021 is an oral Factor Xa inhibitor, an anticoagulant initially being studied for the prevention of venous thromboembolism in patients who have undergone orthopedic surgery. Portola expects to develop PRT054021 for additional indications including stroke prevention in patients with atrial fibrillation and secondary prevention of myocardial infarction and stroke. Factor Xa is a validated target (one for which there are approved drugs on the market), and inhibiting its activity is believed to have superior anticoagulant properties compared to other targets such as thrombin. Portola believes its oral Factor Xa inhibitor will offer several advantages, including a twenty hour pharmacodynamic half-life to support once daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment. In addition, PRT054021 is not excreted in the kidneys and therefore will not require dose adjustment in patients with impaired renal function. PRT054021 is expected to enter Phase III clinical development in the first half of 2008.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. Portola is currently developing two clinical stage antithrombotics. Portola's lead compound, PRT054021, is an oral Factor Xa inhibitor for the prevention of venous thromboembolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for secondary prevention of myocardial infarction (MI) and stroke. Portola's second compound, PRT060128, is an o
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/1/2015)... -- According to a new market research ... (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral), by ... to 2020", published by MarketsandMarkets, the Transfection Reagents and ... by 2020 with a CAGR of 7.2% from 2014 ... ables and 33 F igures ...
(Date:7/1/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/nk3569/future_horizons ... "Future Horizons and Growth Strategies in the European ... Forecasts" report to their offering. ... Blood Banking Market 2015 is a new five-countrystrategic ... and potential market entrants identify and evaluate emerging ...
(Date:7/1/2015)... MARLBOROUGH, Mass. , July 1, 2015 Boston ... call discussing financial results and business highlights for the second ... at 8 a.m. ET. The call will be ... officer, and Dan Brennan , executive vice president and ... conference call will be available via the Boston Scientific website. ...
Breaking Medicine Technology:Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 4European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3Boston Scientific To Webcast Second Quarter 2015 Earnings Call On July 23 2
... TechniScan (OTC Bulletin Board: TSNI ), a ... an automated 3D breast ultrasound imaging system, announced today that ... with Austin, Texas-based Womens3D. These agreements follow ... January 2011 in which they agreed to jointly develop a ...
... PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ... company,s president and chief executive officer, is scheduled ... Markets Healthcare ConferenceWednesday, March 2, 20119:00 a.m. Eastern ... Health Care Conference Tuesday, March 8, 201111:00 a.m. ...
Cached Medicine Technology:Breast Imaging Company, TechniScan, Signs Manufacturing Agreement With Texas Company 2
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... exclusively to healthcare providers, has been retained to lead a national chief ... the top executive search firms in the healthcare industry, B. E. Smith has ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Incentivizing the use ... under control, with discounts as much as 80% or 90% off the prices for ... insurers need to act to mitigate the financial impact of these high-cost generic drugs. ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... the global distribution and marketing of a number of nutritional and beauty products, ... attended the 2015 ECRM Diet, Vitamin & Sports Nutrition conference in Tampa, Florida. ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... platforms and devices, today announced the opening of a new operational office in ... support that enables collaboration across all lines of business for organizations throughout the ...
(Date:7/1/2015)... ... July 01, 2015 , ... First Harvest Financial ... web-based resource where legal cannabis startups can interact with corporate executives, ... medical marijuana advocates looking to strategically enter and capitalize on growing and creating ...
Breaking Medicine News(10 mins):Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 3Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 2Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 3Health News:NPI Executives Report Great Success at ECRM Conference 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 3Health News:First Harvest Financial Partners in Launch of Legal Medical Cannabis Documentary Initiative 2Health News:First Harvest Financial Partners in Launch of Legal Medical Cannabis Documentary Initiative 3
... Julia VanTine HealthDay Reporter , WEDNESDAY, Oct. 27 ... than commonly thought, say researchers who found a lag time ... mutations and the formation of the first cancer cells. ... this often-fatal disease in its early stages, scientists say. ...
... WEDNESDAY, Oct. 27 (HealthDay News) -- Although many Americans are ... many are controlling the condition, the prevalence of high blood ... health officials report. According to a new ... 30 percent of American adults suffer from hypertension. "Overall, ...
... immune system may play a critical role in ensuring the ... new study by researchers at the Stanford University School of ... oncogenes are much more successful in eradicating tumors in the ... cell called a T helper cell. The finding is ...
... Hatfield Professor of Urology in the Department of Urology at ... honored as the 2010 recipient of the Karl Storz Lifetime ... He is also a full Professor of Radiology. ... the Karl Storz lifetime achievement award; having such a distinguished ...
... , WEDNESDAY, Oct. 27 (HealthDay News) -- With ... expert offers breast cancer survivors some guidance on what ... Karen Syrjala, director of biobehavioral sciences and co-director ... Research Center in Seattle, touches upon both the lingering ...
... A team investigating how genes respond to hormonal changes ... of 1.24 million for a five-year study. The ... Manchester Biomedical Research Centre (BRC) is led by Professor ... and leader of The University of Manchester,s Developmental Biomedicine ...
Cached Medicine News:Health News:Pancreatic Cancer Surprisingly Slow to Arise: Study 2Health News:Pancreatic Cancer Surprisingly Slow to Arise: Study 3Health News:Percentage of U.S. Adults With Hypertension Holds Steady at 30% 2Health News:Certain cancer therapies' success depends on presence of immune cell, Stanford study shows in mice 2Health News:Certain cancer therapies' success depends on presence of immune cell, Stanford study shows in mice 3Health News:Certain cancer therapies' success depends on presence of immune cell, Stanford study shows in mice 4Health News:Jefferson urologist awarded Lifetime Achievement Award from Endourological Society 2Health News:Women Urged to Reclaim Their Life After Breast Cancer 2Health News:Manchester team wins $1.9 million grant for 'cell control' study 2
For the qualitative detection of IgG/IgM antibodies to B. burgdorferi...
... surgical-quality loupes available at manufacturer-direct ... innovative optical design, combining superior quality ... with maximum comfort, SheerVision loupes are ... worldwide. Make both a professional and ...
... surgical-quality loupes available at manufacturer-direct ... innovative optical design, combining superior quality ... with maximum comfort, SheerVision loupes are ... worldwide. Make both a professional and ...
... the first manufacturer to offer through-the-lens ... wearer. These next generation loupes feature ... ultra-lightweight design, and are multi-coated lens ... With SheerVision's proprietary SureFit system - ...
Medicine Products: